• Notice of Correction to Application Package for PAR-14-321 "Developing Interventions for Health-Enhancing Physical Activity (R21/R33)"
  (NOT-OD-15-016) Office of Disease Prevention

• Notice of NIH's Interest in Diversity
  (NOT-OD-15-053) National Institutes of Health

• Notice of Legislative Mandates in Effect for FY 2015
  (NOT-OD-15-054) National Institutes of Health

• Notice of Correction to Eligible Individuals in PAR-15-056 "The NCI Transition Career Development Award (K22)"
  (NOT-CA-15-010) National Cancer Institute

• Request for Proposals (RFP) Notice: Clinical Research Coordinating Center for NIDAs Clinical Trials Network
  (NOT-DA-15-039) National Institute on Drug Abuse

• Notice of NIEHS's Participation in RFA-MD-15-005 "NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25)"
  (NOT-ES-15-008) National Institute of Environmental Health Sciences

• New NIGMS Guidelines for Funding Investigators with Substantial Unrestricted Research Support
  (NOT-GM-15-102) National Institute of General Medical Sciences

• Notice of Applicant Information Webinar for RFA-HG-15-001 "Centers for Common Disease Genomics (UM1)"
  (NOT-HG-15-015) National Human Genome Research Institute

• Notice of Applicant Information Webinar for RFA-HG-15-002 "Centers for Mendelian Genomics (UM1)"
  (NOT-HG-15-016) National Human Genome Research Institute

• Notice of Revised NHLBI Policy for the Duration of AIDS-Related Research Project Grants
  (NOT-HL-15-249) National Heart, Lung, and Blood Institute

• Notice of the National Heart, Lung, and Blood Institute (NHLBI) Participation in RFA-MD-15-005 "NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25)"
  (NOT-HL-15-250) National Heart, Lung, and Blood Institute

• Notice of Participation of NIMHD in PA-13-313: "Academic Research Enhancement Award (Parent R15)"
  (NOT-MD-15-003) National Institute on Minority Health and Health Disparities

  (NOT-RM-15-008) NIH Roadmap Initiatives

• Notice of Pre-Application Technical Assistance Webinar for RFA-RM-14-017 Science of Behavior Change Resource and Coordinating Center (U24)
  (NOT-RM-15-009) NIH Roadmap Initiatives

• Reminders Related to the NIH/AHRQ Policy for Application Submission
  (NOT-OD-15-059) Office of the Director, NIH

• Findings of Research Misconduct
  (NOT-OD-15-060) National Institutes of Health

• Salary Limitation on FY 2015 AHRQ Grants, Cooperative Agreements, and Contracts
  (NOT-HS-15-003) Agency for Healthcare Research and Quality

• Reminder to AHRQ Grantees that FY2010 Funds will Expire on September 30, 2015
  (NOT-HS-15-004) Agency for Healthcare Research and Quality

• Notice of the Extension of the Expiration Date for PAR-12-152 "NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01)"
  (NOT-NS-15-011) National Institute of Neurological Disorders and Stroke

• Notice of the Extension of the Expiration Date for PAR-12-163 "NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22)"
REQUESTS FOR APPLICATIONS

- **TITLE: NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25)**
  **SPONSOR:** National Institute of Environmental Health Sciences, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Minority Health and Health Disparities, National Library of Medicine, National Center for Complementary and Alternative Medicine, National Center for Advancing Translational Sciences, Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Behavioral and Social Sciences Research, Office of Strategic Coordination
  **Synopsis:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Big Data to Knowledge (BD2K) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and curriculum development.
  **LOI Due:** February 19, 2015. Application Receipt Date(s): March 19, 2015

- **TITLE: Innovative Molecular Analysis Technologies for Cancer Research (R21)**
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The emphasis of this FOA is on supporting the development of novel molecular and cellular analysis capabilities with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular basis of cancer.
  **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE: Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33)**
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This FOA solicits R33 applications where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed.
  **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE: Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)**
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.
  **Application Receipt/Submission Date(s):** Multiple dates, see announcement.

- **TITLE: Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)**
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development and validation of technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens.
Applications must include preliminary data sufficient to justify the feasibility of the proposed technology, but may still require additional development to reach a generally useful level of functionality for cancer-related research applications.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Pharmacogenomics of Orofacial Pain Management (R01)
  (RFA-DE-16-001)
  **SPONSOR:** National Institute of Dental and Craniofacial Research

**PROGRAM ANNOUNCEMENTS**

- **TITLE:** Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21) (PAR-15-092)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Basic Cancer Research in Cancer Health Disparities (R01) (PAR-15-093)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention intervention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (FI2) (PAR-15-094)
  **SPONSOR:** National Institute of General Medical Sciences
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3) (PAR-15-095)
  **SPONSOR:** National Cancer Institute, National Institutes of Health
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within two years before an assay may undergo clinical validation. The UH3 phase of this FOA supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. In both the UH2 and UH3 phases, clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials. Investigators responding to this FOA must address both UH2 and UH3 phases.
• **TITLE:** Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)  
(PAR-15-096)

**SPONSOR:** National Cancer Institute, National Institutes of Health

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants to this FOA must have an assay whose performance has been analytically validated within specimens similar to those for the intended clinical use of the assay and marker. The UH3 mechanism supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multidisciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44)  
(PA-15-086)

**SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R41/R42)  
(PA-15-087)

**SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Shared Instrumentation Grant (SIG) Program (S10)  
(PAR-15-088)

**SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): May 29, 2015

**OTHER FUNDING OPPORTUNITIES**

• **TITLE:** Alcohol and Substance Abuse Research Program Consortium (ASARP) Award  

**SPONSOR:** Department of Defense CDMRP

**Synopsis:** The ASARP Consortium Award will support the establishment of a Consortium that includes collaborations of multiple organizations and individuals for the purpose of identifying promising compounds with the goal of translating basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD. The Consortium will ultimately consist of a single Management Core as well as basic research and clinical trial sites.

Application Receipt/Submission Date(s): Pre-application due February 26, 2015; Full application due March 5, 2015

• **TITLE:** Damon Runyon Fellowship Award (Damon Runyon Postdoctoral Research Fellowships)  
[http://www.damonrunyon.org/for_scientists/more/fellowship_award_overview](http://www.damonrunyon.org/for_scientists/more/fellowship_award_overview)

**SPONSOR:** Damon Runyon Cancer Research Foundation

Application Receipt/Submission Date(s): March 16, 2015

• **TITLE:** Clinical 'investigator Award  
[http://www.damonrunyon.org/for_scientists/more/clinical_investigator_award_overview](http://www.damonrunyon.org/for_scientists/more/clinical_investigator_award_overview)

**SPONSOR:** Damon Runyon Cancer Research Foundation

Application Receipt/Submission Date(s): February 17, 2015

• **TITLE:** Student Training and Research in Tumor Immunology (sTaRT)  

**SPONSOR:** Cancer Research Institute
- TITLE: Distinguished Scientist Awards  
  SPONSOR: Sontag Foundation

- TITLE: Soy Health Research Program (SHRP)  
  http://thesoynutritioninstitute.com/shrp.php  
  SPONSOR: United Soybean Board

- TITLE: International Awards for Research in Leukemia  
  http://www.ladytatatrust.org/StaticPage/Awards/0  
  SPONSOR: Lady Tata Memorial Trust

- TITLE: Research Grants  
  https://ictr.research.bcm.edu/R5T801F3WH2/CBTF/Default.aspx  
  SPONSOR: Childhood Brain Tumor Foundation

- TITLE: Miller-Dwan Foundation Innovations Fund  
  http://mdfoundation.org/grants/apply/#mdf  
  SPONSOR: Miller-Dwan Foundation

- TITLE: Hollis Brownstein Research Grants Program  
  http://www.allbloodcancers.org/hollis-brownstein-research-grants  
  SPONSOR: Leukemia Research Foundation, Inc.